HCMC Flags Going Concern, Material Weaknesses in Q2 Report
HCMC is trading near its 52-week low of $0 (0.0% above the low) on light trading volume (0.2× avg).
Summary
HCMC's Q2 10-Q shows continued losses, a going concern warning, material weaknesses, and new financing that could be highly dilutive at current prices.
Key Events · Earnings and Guidance · HCMC
-
Going Concern Warning
With $1.2M in cash and negative working capital of $0.7M, management states substantial doubt about the company's ability to continue as a going concern without additional capital.
-
Material Weaknesses
Disclosure controls and internal control over financial reporting are ineffective due to lack of segregation of duties, inadequate IT controls, and insufficient documentation.
-
New Financing
The company entered a $5M Sabby Loan Agreement (initial $500K advance) and a $50K convertible note with Pinz Capital; the note converts at $0.00009 per share, potentially issuing 555.6M shares plus a 250M share warrant.
-
Patent Litigation Loss
PTAB ruled in favor of R.J. Reynolds in March 2026; HCMC filed an appeal on June 1, 2026, with briefs due end of August 2026.
Analysis · HCMC · Manufacturing
The Q2 2026 10-Q from Healthier Choices Management Corp. reveals a net loss of $0.7M for the first half, negative working capital of $0.7M, and a going concern warning. Management also disclosed material weaknesses in internal controls and a new $5M credit facility with Sabby Volatility Warrant Master Fund. Trading near its 52-week low at $0.000001, the company has no revenue from its core products. The filing includes a highly dilutive convertible note with a conversion price of $0.00009, significantly above the current market price, and a warrant for 250M shares. The patent litigation loss against R.J. Reynolds and the delayed Quitcubes launch further cloud the outlook.
At the time of this filing, HCMC was trading at $0.00 on OTC in the Manufacturing sector, with a market capitalization of approximately $527.2K. The 52-week trading range was $0.00 to $0.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.